Hook & thesis
Fulgent Genetics (FLGT) has been through a turbulent year: a large customer moved work in-house, guidance was pulled lower and the stock sold off, but the underlying business is still producing revenue growth and management appears to be taking active steps to rebalance the customer base and defend margins. That combination - operational momentum on the top line and a materially cheaper valuation - creates a high-probability swing trade for disciplined buyers.
I’m constructive on an initial long at $20.42 with a mid-term target of $28.00 (45 trading days) and a stop at $17.50. The math here is straightforward: the market is pricing FLGT at roughly $580M market cap and an EV/Sales near 1.75 despite recurring revenue growth in the diagnostic/esoteric testing market and a recent $82M quarter. If management’s actions to diversify revenue and limit single-customer exposure gain traction, downside is limited relative to upside from a re-rating or multiple recovery.
What the company does and why the market should care
Fulgent is a clinical genomic testing company that sells genetic panels, hereditary cancer testing, carrier screens and tumor profiling. The global esoteric testing market is expected to expand materially over the next several years as personalized medicine and liquid biopsy adoption grow; one industry forecast projects the space from roughly $27.5B in 2025 toward $41.6B by 2031. That macro tailwind matters for Fulgent because it is a price-and-scale business: increasing test volumes and broader test menus can lift revenue and, if managed tightly, margins.
The near-term story that moves the stock is concentration and execution. A single large customer moving work in-house drove a guidance reset and a sharp share-price drop on 02/27/2026, which forced management to respond. The market cares because if Fulgent can replace that lost volume with a diversified customer base and control fixed costs while protecting pricing and reimbursement, the revenue base is sizable enough to sustain a valuation meaningfully above current levels.
Numbers that back the thesis
- Recent quarter: management reported Q2 revenue of $82M, a 15% year-over-year increase (reported 08/01/2025).
- Full-year context: full year 2025 revenue was $322.7M according to company filings and commentary tied to the 02/27/2026 update.
- Valuation snapshot: market cap roughly $579.9M, enterprise value about $560.7M and EV/Sales of ~1.75. Price-to-sales is 1.82 and price-to-book ~0.56.
- Profitability and cash flow: trailing EPS is negative at -$2.60 and free cash flow is deeply negative at -$113.17M, so the current valuation rests on revenue recovery and margin improvement rather than current earnings.
- Balance sheet and leverage: reported debt-to-equity is 0 and current and quick ratios are both ~5.31, suggesting limited near-term liquidity pressure from leverage.
Valuation framing
At an EV/Sales of ~1.75 and market cap near $580M, Fulgent trades at a discount to where many growth-oriented diagnostic peers trade when they have profitable operations and steady revenue visibility. That discount is primarily attributable to three things: negative earnings and cash flow, legal / investigative overhangs, and customer concentration that showed up in early 2026 guidance. If revenue stabilizes and free cash flow losses narrow, a multiple re-rating toward mid-single-digit EV/Sales would be reasonable - which is the core of the upside case.
That said, the valuation is not a free lunch. Negative EPS (-$2.60) and a large negative free cash flow (~-$113M) mean the company must either curb cash burn, accelerate profitable volume growth, or tap capital markets to run the business. Each of those paths carries its own execution risk and possible dilution, so the trade is conditional on management execution and visible improvement in quarterly cash burn.
Catalysts to watch (2-5)
- Quarterly results (next reported quarter): signs of revenue stabilization or sequential growth, especially replacement volume for the customer that moved in-house.
- Customer diversification disclosures: new partnerships or expanded contracts that reduce single-customer concentration.
- Legal developments: resolution or meaningful progress on DOJ civil investigative demands and related securities investigations - positive outcomes would remove a premium discount.
- Margin improvement initiatives: clear cost actions or productivity gains that narrow negative free cash flow in subsequent quarters.
- Short-interest dynamics: a meaningful reduction in days-to-cover from current ~7.9 (as of 06/30/2026) would reduce technical pressure on the stock.
Trade plan (actionable)
Entry: Buy at $20.42. This reflects the current tape and aligns with recent intraday levels.
Stop: $17.50. Placing the stop here limits downside to a level below the recent consolidation low and under the psychological $18 area. If the stop is hit, it signals continued weak execution or another negative surprise.
Target: $28.00. This is the primary mid-term target to be executed within a mid term (45 trading days) horizon. The target sits north of the 52-week midpoint and assumes one of two paths: either revenue recovery drives a multiple expansion or improving cash flow reduces the valuation discount.
Time frames and sizing: I recommend running this as a swing trade for mid term (45 trading days) with a modest position size given the legal/operational risks. If the company posts a clean quarter and management shows tangible progress on replacing lost volume, consider holding toward a longer-term upside target of $34.00 over long term (180 trading days). Conversely, trim on a fast move above $28 to lock gains and re-evaluate if fundamentals haven’t meaningfully improved.
Technical & market structure notes
Technically the stock has been improving: the 10-day SMA ($20.76) and 20-day EMA ($19.82) are above the 50-day moving averages, and the RSI sits at ~60, indicating constructive momentum without being overbought. Short-interest has risen at times, providing potential squeeze dynamics if positive news arrives; days-to-cover was ~7.9 on 06/30/2026.
Risks and counterarguments
- Legal / regulatory overhang: multiple law firms and a DOJ civil investigative demand have been reported. An adverse development could materially damage valuation and cause additional write-downs or penalties.
- Customer concentration: the largest customer moving work in-house is a tangible event. If Fulgent cannot replace that volume at acceptable margins, revenue and cash flow will deteriorate further.
- Negative cash flow and profitability: free cash flow was -$113.17M and EPS -$2.60. Continued cash burn may force equity raises or other dilutive financing that would hurt returns for existing shareholders.
- Reimbursement and pricing pressure: diagnostics and esoteric testing are sensitive to reimbursement changes. Any adverse policy changes or tougher commercial payor dynamics would compress margins.
- Execution risk on diversification: management may announce initiatives to diversify customers, but execution takes time and upfront investment - the market may penalize execution gaps.
Counterargument - The stock could be a value trap: cheap multiples often reflect structural problems beyond temporary disruption. If the regulatory and legal issues are material, or if reimbursements tighten meaningfully, the company might trade persistently lower despite attempts at diversification. For risk-averse investors, waiting for a clean quarter and better cash-flow trends before stepping in is a perfectly valid strategy.
Conclusion and what would change my mind
My base case is constructive: Fulgent at $20.42 presents a pragmatic swing opportunity because the business still generates material revenue, the esoteric testing market remains an expanding addressable market, and valuation is inexpensive relative to growth potential if execution improves. The trade assumes management can replace lost customer volume or cut enough incremental costs to narrow cash burn and restore confidence.
I would change my view if any of the following occur: (1) further guidance weakness or another large customer loss on similar terms; (2) material adverse findings from the DOJ or settlement costs that erode the balance sheet; or (3) continued steep free cash flow deterioration without a credible path to profitability. If instead we see revenue stabilization, improving margins and no new legal shocks, that would reinforce the bullish case and justify adding to the position on strength.
Execution checklist (before you trade)
- Confirm entry liquidity around $20.42 and set an OCO order (entry + stop) to enforce discipline.
- Position-size to limit downside to a comfortable dollar amount given the stop at $17.50.
- Monitor quarterly results and any legal disclosures closely; be prepared to tighten stops or exit on fresh negative updates.
Bottom line: Fulgent is a live trade. Buy a starter position at $20.42, target $28.00 over the next 45 trading days, and protect capital with a $17.50 stop. Keep position sizing modest given the legal and customer-concentration risks; add only if you see clean execution and cashflow improvement.